Volume 14, Issue 4 (Volume 14, No 4 2024)
jdc 2024, 14(4): 215-220 |
Back to browse issues page
1- Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran * Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran , mnourizadeh80@gmail.com
2- Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran * Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
2- Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran * Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
Abstract: (1310 Views)
Methotrexate (MTX) is a freely available medication. However, regardless of extensive off-label consumption, FDA labeling does not include accepted for the consumption of MTX for many inflammatory skin diseases in pediatrics, containing morphea, psoriasis, atopic dermatitis, and alopecia areata. Lacking published healing recommendations makes the clinicians unsure about prescribing MTX in an off-label manner especially in children. Present study, was conducted to review the use of MTX to heal pediatric inflammatory skin disorders.
The evidence and consent based advices will assistance safe and successful use of MTX for the underserved population of pediatrics who may benefit from this valuable, time-honored medication.
The evidence and consent based advices will assistance safe and successful use of MTX for the underserved population of pediatrics who may benefit from this valuable, time-honored medication.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |